Back

The Drug-Induced Respiratory Disease Website and App

Antiviral therapy/agents (direct-acting) against hepatitis C virus

The role of specific drug or drugs can be difficult to evaluate in those patients receiving combinatorial therapy. Please consult current list or lists of antiviral agents elsewhere at all time, as a class effect is possible if not likely

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I - Interstitial/parenchymal lung disease

II - Pulmonary edema - Acute lung injury - ARDS

III - Pulmonary/alveolar/airway hemorrhage/bleeding

IV - Airway involvement

V - Pleural and/or pericardial involvement

X - Systemic/Distant conditions, syndromes and reactions

XI - Miscellaneous

XV - Pathology

XVI - Imaging

XVII - Infections & related conditions

XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA